Sanofi Pasteur
LYON, France, September 20, 2011 -
- Vaccine strain used in the production of oral polio vaccines
against type 3 poliovirus -
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today it is donating to the World Health Organization (WHO) a vaccine strain used for polio eradication.
LYON, France, July 7, 2011 -
-
Newcomer's
Biopharmaceutical Experience to
Further Develop European
Joint-Venture -
MSD, known as Merck in the United States and Canada (NYSE: MRK),
and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN
and NYSE: SNY), the two partner companies in Sanofi Pasteur MSD,
announce today the appointment of Dr.
LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group
(EURONEXT: SAN and NYSE: SNY), today will participate in the first
international bell-ringing event by a company listed on NYSE Euronext.
LYON, France, February 21, 2011 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group
(EURONEXT: SAN and NYSE: SNY), announced today that it is partnering with the
International Vaccine Institute (IVI) to support the recently launched Dengue
Vaccine Initiative (DVI).
LYON, France, November 4, 2010 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group
(EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in
final stage of clinical development.
More News
- Un nuevo estudio para acelerar el desarrollo de una vacuna innovadora contra el dengue, en uno de los pases ms afectados del mundo
- Sanofi Pasteur Files for Approval in Thailand and Australia of IMOJEV(TM), Single-dose Japanese Encephalitis Vaccine
- Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded to Singapore and Vietnam
